Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro.

@article{BarAm2007AminoindanAH,
  title={Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro.},
  author={Orit Bar-Am and Tamar Amit and Moussa B. H. Youdim},
  journal={Journal of neurochemistry},
  year={2007},
  volume={103 2},
  pages={500-8}
}
The anti-Parkinson, selective irreversible monoamine oxidase B inhibitor drug, rasagiline (Azilect), recently approved by the US Food and Drug Administration, has been shown to possess neuroprotective-neurorescue activities in in vitro and in vivo models. Recent preliminary studies indicated the potential neuroprotective effect of the major metabolite of rasagiline, 1-(R)-aminoindan. In the current study, the neuroprotective properties of 1-(R)-aminoindan were assessed employing a cytotoxic… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 32 extracted citations

Explaining ADAGIO: a critical review of the biological basis for the clinical effects of rasagiline.

Movement disorders : official journal of the Movement Disorder Society • 2011
View 3 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…